AtriCure (NASDAQ:ATRC) Releases Q4 2025 Earnings Guidance

AtriCure (NASDAQ:ATRC) issued an update on its fourth quarter 2025 earnings guidance on Monday morning. The company provided EPS guidance of -0.210–0.180 for the period, compared to the consensus EPS estimate of -0.050. The company issued revenue guidance of $140.5 million-$140.5 million, compared to the consensus revenue estimate of $139.2 million. AtriCure also updated its FY 2025 guidance to EPS.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Zacks Research upgraded AtriCure from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 6th. Weiss Ratings restated a “sell (d-)” rating on shares of AtriCure in a report on Wednesday, October 8th. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a research report on Thursday, October 30th. Canaccord Genuity Group lifted their target price on AtriCure from $53.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Finally, JPMorgan Chase & Co. increased their price target on AtriCure from $42.00 to $48.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $52.44.

AtriCure Trading Down 5.7%

ATRC traded down $2.35 on Monday, hitting $39.12. 205,962 shares of the company were exchanged, compared to its average volume of 414,424. The stock has a market capitalization of $1.94 billion, a PE ratio of -64.01 and a beta of 1.40. AtriCure has a 12 month low of $28.29 and a 12 month high of $43.18. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.85 and a current ratio of 3.87. The firm has a fifty day simple moving average of $37.67 and a two-hundred day simple moving average of $35.78.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Wednesday, October 29th. The medical device company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.10. AtriCure had a negative net margin of 5.55% and a negative return on equity of 2.54%. The business had revenue of $134.27 million during the quarter, compared to analyst estimates of $131.25 million. During the same period in the prior year, the business earned ($0.17) EPS. The company’s revenue for the quarter was up 15.8% on a year-over-year basis. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. Sell-side analysts expect that AtriCure will post -0.6 earnings per share for the current year.

Insider Activity

In other news, Director Sven Wehrwein sold 4,967 shares of the company’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $38.00, for a total transaction of $188,746.00. Following the completion of the sale, the director owned 34,374 shares of the company’s stock, valued at $1,306,212. This represents a 12.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Maggie Yuen sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $35.72, for a total transaction of $107,160.00. Following the sale, the director owned 11,371 shares of the company’s stock, valued at $406,172.12. This trade represents a 20.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 18,166 shares of company stock valued at $676,378 in the last 90 days. 3.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On AtriCure

Hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP boosted its position in shares of AtriCure by 8.1% during the third quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company’s stock valued at $151,296,000 after buying an additional 322,818 shares during the period. Oberweis Asset Management Inc. bought a new stake in shares of AtriCure in the 3rd quarter valued at about $5,411,000. First Trust Advisors LP acquired a new position in shares of AtriCure during the second quarter worth $4,353,000. Bank of America Corp DE raised its stake in AtriCure by 15.7% in the second quarter. Bank of America Corp DE now owns 710,173 shares of the medical device company’s stock valued at $23,272,000 after buying an additional 96,313 shares during the last quarter. Finally, Algert Global LLC raised its position in AtriCure by 162.2% during the 3rd quarter. Algert Global LLC now owns 147,038 shares of the medical device company’s stock worth $5,183,000 after buying an additional 90,969 shares during the last quarter. Hedge funds and other institutional investors own 99.11% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.